Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meronem versus Meronem + Avalox in severe sepsis and septic shock
2006-006984-21Phase 3Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- Feb 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in sepsis and septic shock comparing Meronem monotherapy with Meronem + Avalox combination (2 arms). Primary endpoint: Average total SOFA score until end of trial (up to 14 days). Started Feb 2007; status: completed.
02
Drugs
meropenemmoxifloxacin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2006-006984-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006984-21.